E
Emmanuel Clave
Researcher at French Institute of Health and Medical Research
Publications - 65
Citations - 3337
Emmanuel Clave is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Hematopoietic stem cell transplantation & Transplantation. The author has an hindex of 28, co-authored 55 publications receiving 2973 citations. Previous affiliations of Emmanuel Clave include National Institutes of Health & Finnish Red Cross.
Papers
More filters
Journal ArticleDOI
Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses.
Richard W. Childs,Emmanuel Clave,N. Contentin,D. Jayasekera,Nancy F. Hensel,Susan F. Leitman,Elizabeth J. Read,Corey A. Carter,E. Bahceci,Neal S. Young,Austin John Barrett +10 more
TL;DR: The results emphasize the importance of lineage-specific chimerism analysis to successfully manipulate engraftment after nonmyeloablative allogeneic PBSC transplantation.
Journal ArticleDOI
Cytotoxic T Lymphocytes Specific for a Nonpolymorphic Proteinase 3 Peptide Preferentially Inhibit Chronic Myeloid Leukemia Colony-Forming Units
Jeffrey J. Molldrem,Emmanuel Clave,Yin Zheng Jiang,Dimitrios Mavroudis,Anastasios Raptis,Nancy F. Hensel,Vaishali Agarwala,A. John Barrett +7 more
TL;DR: Results show that PR1-specific allogeneic T cells preferentially inhibit leukemic CFU-GM based on overexpression of proteinase 3, and thatproteinase 3-specific CTL could be used for leukemia-specific adoptive immunotherapy.
Journal ArticleDOI
A broad T-cell repertoire diversity and an efficient thymic function indicate a favorable long-term immune reconstitution after cord blood stem cell transplantation.
Kimmo Talvensaari,Emmanuel Clave,Corinne Douay,Claire Rabian,Laurent Garderet,Marc Busson,Federico Garnier,Daniel C. Douek,Eliane Gluckman,Dominique Charron,Antoine Toubert +10 more
TL;DR: Data indicate an efficient thymic regeneration pathway from CB lymphoid progenitors despite the low number of cells infused compared to bone marrow, arguing for a complete clinical immune recovery after CB transplantation.
Journal ArticleDOI
Successful Treatment of Metastatic Renal Cell Carcinoma With a Nonmyeloablative Allogeneic Peripheral-Blood Progenitor-Cell Transplant: Evidence for a Graft-Versus-Tumor Effect
Richard W. Childs,Emmanuel Clave,John F. Tisdale,Michelle Plante,Nancy F. Hensel,John Barrett +5 more
TL;DR: The complete regression of metastatic disease, which has now been maintained for more than 1 year, is compatible with a graft-versus-tumor effect.
Journal ArticleDOI
T cell-depleted bone marrow transplantation and delayed T cell add- back to control acute GVHD and conserve a graft-versus-leukemia effect
Austin John Barrett,Dimitrios Mavroudis,John F. Tisdale,Jeffrey J. Molldrem,Emmanuel Clave,Cynthia E. Dunbar,Michele Cottler-Fox,Sheila Phang,Corey A. Carter,P. Okunnieff,Neal S. Young,Elizabeth J. Read +11 more
TL;DR: Results indicate that the risk of acute GVHD is low following substantial T cell doses, transfused 45 days after transplant, using cyclosporine prophylaxis and a graft-versus-leukemia effect was conserved.